ERYTECH Pharma has patented and conducted clinical trial of asparaginase in RBCs (GRASPA) for the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia [81,82,83], and is currently conducting clinical trials of asparaginase-loaded RBCs (Eryaspase) for the treatment of metastatic pancreatic cancer (trial TRYbeCA-1) [84,85,86] and of triple-negative breast cancer (trial TRYbeCA-2). This evidence concerns the gene ASPG and triple-negative breast carcinoma.